Literature DB >> 19745811

Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models.

Damla Pinar Karpinar1, Madhu Babu Gajula Balija, Sebastian Kügler, Felipe Opazo, Nasrollah Rezaei-Ghaleh, Nora Wender, Hai-Young Kim, Grit Taschenberger, Björn H Falkenburger, Henrike Heise, Ashutosh Kumar, Dietmar Riedel, Lars Fichtner, Aaron Voigt, Gerhard H Braus, Karin Giller, Stefan Becker, Alf Herzig, Marc Baldus, Herbert Jäckle, Stefan Eimer, Jörg B Schulz, Christian Griesinger, Markus Zweckstetter.   

Abstract

The relation of alpha-synuclein (alphaS) aggregation to Parkinson's disease (PD) has long been recognized, but the mechanism of toxicity, the pathogenic species and its molecular properties are yet to be identified. To obtain insight into the function different aggregated alphaS species have in neurotoxicity in vivo, we generated alphaS variants by a structure-based rational design. Biophysical analysis revealed that the alphaS mutants have a reduced fibrillization propensity, but form increased amounts of soluble oligomers. To assess their biological response in vivo, we studied the effects of the biophysically defined pre-fibrillar alphaS mutants after expression in tissue culture cells, in mammalian neurons and in PD model organisms, such as Caenorhabditis elegans and Drosophila melanogaster. The results show a striking correlation between alphaS aggregates with impaired beta-structure, neuronal toxicity and behavioural defects, and they establish a tight link between the biophysical properties of multimeric alphaS species and their in vivo function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19745811      PMCID: PMC2771093          DOI: 10.1038/emboj.2009.257

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  51 in total

1.  Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells.

Authors:  W Zhou; M S Hurlbert; J Schaack; K N Prasad; C R Freed
Journal:  Brain Res       Date:  2000-06-02       Impact factor: 3.252

Review 2.  Alpha-synuclein and neurodegenerative diseases.

Authors:  M Goedert
Journal:  Nat Rev Neurosci       Date:  2001-07       Impact factor: 34.870

Review 3.  The Caenorhabditis elegans dopaminergic system: opportunities for insights into dopamine transport and neurodegeneration.

Authors:  Richard Nass; Randy D Blakely
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002-01-10       Impact factor: 13.820

4.  A Drosophila model of Parkinson's disease.

Authors:  M B Feany; W W Bender
Journal:  Nature       Date:  2000-03-23       Impact factor: 49.962

5.  An improved broadband decoupling sequence for liquid crystals and solids.

Authors:  B M Fung; A K Khitrin; K Ermolaev
Journal:  J Magn Reson       Date:  2000-01       Impact factor: 2.229

6.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.

Authors:  E Masliah; E Rockenstein; I Veinbergs; M Mallory; M Hashimoto; A Takeda; Y Sagara; A Sisk; L Mucke
Journal:  Science       Date:  2000-02-18       Impact factor: 47.728

7.  Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity.

Authors:  S J Tabrizi; M Orth; J M Wilkinson; J W Taanman; T T Warner; J M Cooper; A H Schapira
Journal:  Hum Mol Genet       Date:  2000-11-01       Impact factor: 6.150

8.  Conformational properties of alpha-synuclein in its free and lipid-associated states.

Authors:  D Eliezer; E Kutluay; R Bussell; G Browne
Journal:  J Mol Biol       Date:  2001-04-06       Impact factor: 5.469

9.  Dependence of alpha-synuclein aggregate morphology on solution conditions.

Authors:  Wolfgang Hoyer; Thomas Antony; Dmitry Cherny; Gudrun Heim; Thomas M Jovin; Vinod Subramaniam
Journal:  J Mol Biol       Date:  2002-09-13       Impact factor: 5.469

10.  The fold of alpha-synuclein fibrils.

Authors:  Marçal Vilar; Hui-Ting Chou; Thorsten Lührs; Samir K Maji; Dominique Riek-Loher; Rene Verel; Gerard Manning; Henning Stahlberg; Roland Riek
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-12       Impact factor: 11.205

View more
  168 in total

1.  Effects of curvature and composition on α-synuclein binding to lipid vesicles.

Authors:  Elizabeth R Middleton; Elizabeth Rhoades
Journal:  Biophys J       Date:  2010-10-06       Impact factor: 4.033

2.  Supramolecular non-amyloid intermediates in the early stages of α-synuclein aggregation.

Authors:  Jonathan A Fauerbach; Dmytro A Yushchenko; Sarah H Shahmoradian; Wah Chiu; Thomas M Jovin; Elizabeth A Jares-Erijman
Journal:  Biophys J       Date:  2012-03-06       Impact factor: 4.033

Review 3.  A predictable worm: application of Caenorhabditis elegans for mechanistic investigation of movement disorders.

Authors:  Paige M Dexter; Kim A Caldwell; Guy A Caldwell
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

4.  Two different binding modes of α-synuclein to lipid vesicles depending on its aggregation state.

Authors:  Tobias Högen; Johannes Levin; Felix Schmidt; Mario Caruana; Neville Vassallo; Hans Kretzschmar; Kai Bötzel; Frits Kamp; Armin Giese
Journal:  Biophys J       Date:  2012-04-03       Impact factor: 4.033

5.  A soluble α-synuclein construct forms a dynamic tetramer.

Authors:  Wei Wang; Iva Perovic; Johnathan Chittuluru; Alice Kaganovich; Linh T T Nguyen; Jingling Liao; Jared R Auclair; Derrick Johnson; Anuradha Landeru; Alana K Simorellis; Shulin Ju; Mark R Cookson; Francisco J Asturias; Jeffrey N Agar; Brian N Webb; Chulhee Kang; Dagmar Ringe; Gregory A Petsko; Thomas C Pochapsky; Quyen Q Hoang
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-17       Impact factor: 11.205

Review 6.  Protein degradation pathways in Parkinson's disease: curse or blessing.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  Acta Neuropathol       Date:  2012-06-29       Impact factor: 17.088

7.  Aggregate clearance of α-synuclein in Saccharomyces cerevisiae depends more on autophagosome and vacuole function than on the proteasome.

Authors:  Doris Petroi; Blagovesta Popova; Naimeh Taheri-Talesh; Stefan Irniger; Hedieh Shahpasandzadeh; Markus Zweckstetter; Tiago F Outeiro; Gerhard H Braus
Journal:  J Biol Chem       Date:  2012-06-21       Impact factor: 5.157

Review 8.  Molecular chaperones in Parkinson's disease--present and future.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

Review 9.  α-Synuclein aggregation modulation: an emerging approach for the treatment of Parkinson's disease.

Authors:  Sushil K Singh; Aloke Dutta; Gyan Modi
Journal:  Future Med Chem       Date:  2017-06-20       Impact factor: 3.808

Review 10.  α-Synuclein oligomers and clinical implications for Parkinson disease.

Authors:  Lorraine V Kalia; Suneil K Kalia; Pamela J McLean; Andres M Lozano; Anthony E Lang
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.